Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada

201655 citationsJournal Articlegold Open Access

Authors

Compared with sunitinib, pazopanib is likely to be a cost-effective option for first-line treatment of mrcc from a Canadian health care perspective.

Published in: Current Oncology

Volume 23, Issue 4, pp. 340-354

Field-Weighted Citation Impact: 4.61